In people having chronic rhinosinusitis with nasal polyps, an exhalation delivery system with fluticasone effectively decreases symptoms and improves the quality of life.

A study was carried out to compare the exhalation delivery system with fluticasone (EDS-FLU) therapy responses in people who have never had sinus surgery and people having recurring symptoms following endoscopic sinus surgery (ESS).

For exploratory analyses, data pooling was done from 2 controlled studies (NAVIGATE I and II). A comparison of quality-of-life, polyp grade, and chronic rhinosinusitis symptoms was done between patients without prior ESS and those who had former ESS.

As estimated by nasal polyp grade along with several symptom and functioning/quality-of-life outcomes (Patient Global Impression of Change, Rhinosinusitis Disability Index, Sinonasal Outcomes Test, and Congestion Score), remarkable and comparable advantages were witnessed in unoperated patients (EDS-FLU 372μg [n=111], EDS-FLU 186μg [n=108], and EDS-placebo [n=108]) and in patients with prior ESS (EDS-FLU 372μg [n=49], EDS-FLU 186μg [n=52], and EDS-placebo [n=53]) treated with EDS-FLU.

Numerically higher responses (but not statistically) to the increased dose were depicted by multiple outcomes (Sinonasal Outcomes Test, Rhinosinusitis Disability Index, and polyp grade) in formerly operated people, unlike surgery-naive people.

Chronic rhinosinusitis with nasal polyps patients with recurrent symptoms following sinus surgery who receive EDS-FLU improved remarkably across a range of relevant measures, including polyp grade, symptoms, and quality of life/functioning. In people with prior ESS, the higher dose (2 sprays per nostril twice daily) might offer higher benefits compared to the lower dose (1 spray per nostril twice daily).